Nearly 40,000 bottles of one of the most widely sold over-the-counter eye drops in the country have been recalled because the manufacturer cannot confirm the product is sterile.
Prestige Brands Holdings is recalling 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief, distributed nationwide by Medtech Products Inc. The FDA enforcement report gives the reason as a "lack of assurance of sterility" and describes the action as prompted by potential contamination. The agency classified it as Class II.
The households that need to act are specific. This is a single lot, and a bottle from any other lot is not covered. The affected product carries an expiration date more than a year away, which means bottles in medicine cabinets and bathroom drawers are still well within their usable window.
Identifying the Recalled Bottle by Lot and Expiration
The recall covers Clear Eyes Maximum Itchy Eye Relief in 0.5 fluid ounce, or 15 milliliter, dropper bottles from lot 2552A, with an expiration date of September 30, 2027.
Additional identifiers are the National Drug Code 67172-999-01 and the UPC 6 78112 65920 3. The FDA recall number is D-0766-2026.
The lot code is the single thing that matters here, and it is the thing most people never look at. It is printed on the bottle and carton rather than shown on the front label, so checking requires picking the bottle up and turning it over rather than glancing at the shelf.
Consumers with an affected bottle are advised to stop using it and return it where possible. Clear Eyes products are sold at essentially every major pharmacy and grocery chain, and most retailers process recall returns without a receipt.
Sterility Assurance Is Not the Same as Confirmed Contamination
This distinction determines how alarmed anyone should be, and it gets flattened in most coverage.
A lack of assurance of sterility is a manufacturing finding. It means the process that is supposed to guarantee a sterile product could not be verified to have done so. It does not mean a specific organism was found in a specific bottle. The FDA enforcement report does not identify any contaminant, and no injuries have been publicly linked to this lot.
The Class II designation reflects that. The FDA reserves Class II for situations where exposure may cause temporary or medically reversible health consequences, or where the probability of serious harm is remote. It sits below Class I, which is used when there is a reasonable probability of serious injury or death.
That framing is not a dismissal. It is the agency's own assessment of a product where the manufacturer chose to pull inventory rather than defend it, which is generally the appropriate response to a sterility question. Other entries on the FDA recalls and safety alerts page show how routinely ophthalmic products draw this treatment.
The Eye's Missing Defenses Explain the Caution
Eye drops occupy an unusual position among consumer products because the eye lacks the defenses that protect most other routes of exposure.
Something swallowed passes through stomach acid and an immune system built around the gut. Something applied to intact skin encounters a barrier evolved to keep microbes out. A drop placed on the ocular surface bypasses both. The cornea has no blood vessels of its own, which limits how readily immune cells reach an infection once one begins.
That is why ophthalmic products are held to sterility standards rather than general cleanliness standards, and why regulators treat a sterility failure in an eye drop differently from the same failure in a lotion.
The historical reference point is recent. In 2023, artificial tears contaminated with a drug-resistant strain of Pseudomonas aeruginosa were linked by the CDC to dozens of infections across multiple states, including cases of permanent vision loss and at least one death. MedicalDaily has previously examined how sterility failures translate into risk for eye products.
Nothing currently connects the Clear Eyes recall to that history beyond category. The 2023 episode involved a confirmed organism and confirmed patient harm. This one involves neither so far. The comparison explains why regulators act quickly on eye drops, not what happened here.
Anyone who used drops from this lot and has developed eye pain, redness that is worsening rather than improving, discharge, light sensitivity, blurred vision or any change in vision should contact a clinician or eye care provider rather than waiting. Those symptoms warrant evaluation regardless of which product caused them. Adverse reactions can also be reported through the FDA MedWatch program, which is how patterns get detected.
A Three Week Gap Between Recall and Public Attention
The timeline here is worth stating clearly, because it is being reported inconsistently.
Prestige initiated the voluntary recall on July 29. The FDA classified it as Class II on August 14. Consumer coverage began circulating widely this week. So a shopper learning about it now is learning about an action taken roughly three weeks ago, during which affected bottles remained in homes.
That lag is normal rather than scandalous. Enforcement reports are published weekly, and classification takes time because the agency assesses the health hazard before assigning a class. But it explains why a recall can feel like breaking news when the product left the supply chain weeks earlier, and it is the reason checking a cabinet is more useful than checking a store shelf.
The recall remains listed as ongoing, meaning the FDA has not verified that all affected product has been recovered. Prestige, which is based in Tarrytown, New York, and whose portfolio also includes Dramamine, Chloraseptic and Monistat, had not commented publicly on the recall as of this week. MedicalDaily has also tracked a much larger prescription steroid eye drop recall this year.
What remains unknown is what specifically failed in the sterility assurance process, whether any organism was ever detected, and whether other lots or products from the same production line could be implicated. None of those questions has been answered in the enforcement record.
Key Questions Answered
Which product is recalled? Clear Eyes Maximum Itchy Eye Relief, 0.5 fluid ounce or 15 milliliter dropper bottles, lot 2552A, expiration September 30, 2027. No other Clear Eyes products or lots are covered.
Why was it recalled? The FDA enforcement report cites a lack of assurance of sterility due to potential contamination. No specific contaminant has been identified.
Has anyone been hurt? No injuries have been publicly linked to this lot, and the FDA has not identified any adverse events in the enforcement record.
What does Class II mean? Exposure may cause temporary or medically reversible health effects, or the chance of serious harm is remote. It is below Class I, the highest risk tier.
When did this actually happen? The company initiated the recall on July 29 and the FDA classified it on August 14. Wide consumer coverage began this week, so affected bottles may still be in homes.
What should I do with an affected bottle? Stop using it and return it to the retailer. Most chains process recall returns without a receipt.
When should I see a doctor? Contact a clinician or eye care provider for eye pain, worsening redness, discharge, light sensitivity, blurred vision or any change in vision after using drops from this lot.
